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Abstract
ROLE OF ROCK AND PKC IN REGULATION OF CONTRACTION OF 
PERMEABILIZED FEMORAL ARTERIAL SMOOTH MUSCLE
by Brendan M. Browne, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Masters of 
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Director: Paul H. Ratz, Ph.D.
Professor, Department of Biochemistry and Pediatrics
KCl is traditionally used as a stimulus to examine the role of increases in cytosolic Ca2+ 
on the regulation of smooth muscle contraction. KCl bypasses GPCR activation, thereby 
avoiding activation of additional cell  signaling systems, such as phospholipase C and 
PKC that  are  inherent  to  Gαq and  Gα12/13 stimulation.  GPCR activation  causes  Ca2+ 
sensitization (greater force for a given increase in Ca2+) by a ROCK- and PKC-dependent 
inhibition of myosin light chain (MLC) phosphatase. Recent studies have demonstrated 
that KCl can also produce Ca2+ sensitization, implying that Ca2+ itself may induce Ca2+ 
sensitization.  To  test  the  hypothesis  that  Ca2+ can  induce  Ca2+ sensitization,  we 
permeabilized rabbit femoral artery rings with β-escin and subjected the tissues to a Ca2+ 
concentration response curve in the absence (control) and presence of selective inhibitors 
of ROCK and PKC, the general ser/thr kinase inhibitor, staurosporine, and the MLCK 
inhibitor, wortmannin. For a comparison, tissues permeabilized with  β-escin were also 
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contracted with the  α-adrenergic agonist, phenylephrine (PE), and exposed to the same 
complement of inhibitors. Interestingly, Ca2+-induced contraction was inhibited by a PKC 
inhibitor in β-escin-permeabilized tissue. Wortmannin and staurosporine nearly abolished 
Ca2+-induced contraction. The ROCK inhibitor, H-1152, significantly reduced Ca2+- and 
PE-induced  contractions  in  β-escin  permeabilized  tissues.   Western  blots  showed 
significant  decreases in basal  MYPT1-pThr853 by ROCK inhibitors  and reduction of 
MLC-p by ROCK and PKC inhibitors. These data support our hypothesis that elevations 
in Ca2+ or constitutive ROCK activity may cause ROCK-dependent Ca2+ sensitization. 
Moreover,  data  also  suggest  the  possibility  of  PKC-directed  activation  of  the 
RhoA/ROCK cascade.  Once  the  mechanism for  smooth  muscle  Ca2+ sensitization  is 
understood,  advanced  treatments  for  vascular  hyper-contraction  disorders,  such  as 
vasospasm and hypertension, may be possible.
ix

INTRODUCTION
1.1 Basic smooth muscle physiology 
Vertebrate muscle contracts due to actin-myosin cross bridge cycling, in which 
thick and thin muscle filaments slide across one another, shortening the muscle cell and 
generating force.   A transient  increase of  intracellular  calcium ([Ca2+]i)  serves  as  the 
cellular  signal  to  produce appreciable  levels  of  tension  via  actomyosin  hydrolysis  of 
adenosine triphosphate (ATP).  All muscle types – skeletal, cardiac and smooth – employ 
similar  contractile  processes,  but  there  are  numerous  structural  and  functional 
components specific to smooth muscle.
Smooth  muscle  is  uni-nucleated,  non-striated  muscle  found  predominantly  in 
hollow  organs,  including  vasculature,  respiratory  airways,  the  urinary  bladder,  the 
gastrointestinal  tract  and  others.   These  systems  utilize  smooth  muscle  to  facilitate 
motility and maintain organ dimensions against imposed forces.  Smooth muscle consists 
of two subtypes – phasic and tonic – based on different kinetics and force development 
profiles from KCl-induced contraction.  Upon activation, phasic muscle exhibits rapid 
force development immediately followed by relaxation to the initial passive tension, e.g. 
phasic contraction in gastrointestinal peristalsis to promote food motility.  Alternately, 
tonic smooth muscle demonstrates an initial  phasic contraction followed by sustained 
monotonic elevation of muscle tone.  This persistent muscle tone is utilized throughout 
the vascular system to dictate blood pressure.
A  unique  characteristic  of  smooth  muscle  is  the  absence  of  troponin  as  a 
regulatory molecule.  In striated muscle, the troponin-tropomyosin complex covers the 
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myosin II attachment sites on the globular actin thin filament.  With sufficient increase of 
[Ca2+]i,  troponin-C binds Ca2+ and the complex undergoes a conformational change to 
expose the binding sites for myosin II heads.  Provided that ATP is present, myosin II 
ATPase will bind globular actin and proceed with cross-bridge cycling to generate force. 
This mechanism of regulation ensures that the cell contains sufficient energy in the form 
of ATP and an appropriate Ca2+ stimulus to initiate muscle contraction.  Although it is 
devoid of troponin, smooth muscle exhibits thin filament regulation utilizing the proteins 
calponin and caldesmon (Earley, Su et al. 1998, Gusev 2001). 
Smooth muscle exhibits some degree of thin filament regulation, but the primary 
means to control force development is through phosphorylation of a 20-kilodalton (kDa) 
regulatory myosin light chain (MLC), a subunit of myosin II that comprises the thick 
filament of the contractile apparatus.  MLC phosphorylation is not necessary for striated 
muscle  contraction,  but  smooth  muscle  requires  phosphorylation  at  a  specific  MLC 
peptide to increase actomyosin ATPase activity and cross-bridge cycling to a significant 
rate (Cassidy, Hoar et al. 1979).  Unphosphorylated MLC abrogates ATP exchange in 
myosin heads and thus precludes the development of force.
Since  a  dominant  physiological  function  of  smooth  muscle  is  maintenance  of 
muscle  tone,  tonic  muscle  must  sustain  considerable  tension  while  exhibiting 
considerable energy economy.  Isometric force continues to increase monotonically to a 
sustained steady-state in tonic smooth muscle despite decreased MLC phosphorylation, 
[Ca2+]i,  cross-bridge  cycling  rate  and  ATP  consumption  (Kamm  and  Stull  1985). 
Although the molecular process for persistent tonic force has been researched for nearly 
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three  decades,  no  conclusive  mechanism  has  yet  been  devised.   The  current  model 
employs the ‘latch-bridge’ concept (Figure 1), in which dephosphorylation of the MLC of 
an intact actomyosin complex results in a catch-like connection between the thick and 
thin filaments, termed a latch-bridge (Dillon, Aksoy et al. 1981).  Dephosphorylation of 
the MLC regulatory  subunit  in  an attached cross-bridge slows  myosin  II  detachment 
kinetics  relative  to  the  phosphorylated state  (Hai  and  Murphy 1988;  Ratz,  Hai  et  al. 
1989).  Further supporting the latch-bridge hypothesis, a recent study showed that ADP is 
released  faster  in  cross-bridges  with  phosphorylated  MLC,  possibly  due  to  a 
conformational change of the myosin II head (Somlyo, Khromov et al. 2004).  The rigid 
latch-state resists the movement of thick and thin filaments and therefore would maintain 
muscle tone while not requiring continued ATP consumption, accomplishing sufficient 
energy economy.  The latch-bridge hypothesis does explain the efficient maintenance of 
force,  but  biochemical  pathways appear  to  contribute  to  this  phenomenon.   Evidence 
from our laboratory demonstrates that inhibition of RhoA kinase (ROCK) can selectively 
Latch-bridge 
formation
AM
Tonic tension
A + Mp
Cross-bridge 
cycling
AMp
ATP
ADP
Tension
pi
Figure 1. – Schematic of latch-bridge model (modification from Hai, Murphy 1988).  A latch-
bridge  is  the  structure  resulting  from dephosphorylation  of  an  attached  cross-bridge.   Latch-
bridges detach much slower than cross-bridges,  maintaining tonic force in an energy efficient 
manner. A, Actin; Mp, phosphorylated Myosin; AMp, attached Actin and phosphorylated Myosin 
(cross-bridge); AM, attached Actin and unphosphorylated Myosin (latch-bridge); ATP, Adenosine 
Triphosphate; ADP, Adenosine Diphosphate; Pi, phosphate 
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diminish  tonic  force  independent  of  changes  in  [Ca2+]i (Urban,  Berg  et  al.  2003), 
indicating a significant role for ROCK in smooth muscle force maintenance.
1.2 Phosphorylated Myosin Light Chain Ratio
The extent of smooth muscle contraction relies primarily on phosphorylation of 
the regulatory MLC that controls contractile thick filament actomyosin ATPase activity. 
To achieve MLC phosphorylation, muscle cells require ATP as a source of energy and 
phosphate, and generally an increase in [Ca2+]i although Ca2+-independent contractions 
can also occur.  Elevated [Ca2+]i enables binding of Ca2+ to the protein calmodulin (CaM), 
inducing a conformational change (Krueger et al. 1998) that facilitates complexation with 
and activation of myosin light chain kinase (MLCK).  MLCK is a dedicated kinase that 
recognizes and binds specific amino acids – specifically Arg16, Phe22 and Val21 – in the N-
terminus of MLC (Pearson et  al.  1985, Zhi et  al.  1994).   Enzymatic phosphorylation 
occurs  at  Ser-19  of  MLC  (Stull  et  al.  1986),  altering  the  protein’s  C-terminus  to 
potentiate the associated actomyosin ATPase that directs muscle contraction (Trybus and 
Chatman, 1993).  Recent studies with MLCK knockout mice identified other kinases that 
also phosphorylate  MLC, some of  which are  Ca2+-independent  (Somlyo,  Wang et  al. 
2004),  but  MLCK  is  still  considered  the  predominant  kinase  involved  in  MLC 
phosphorylation.
A rapid decrease in tension upon cessation of muscle activation or in the presence 
of relaxing agents is accomplished by constitutive and increased activity of myosin light 
chain phosphatase (MLCP), an enzyme that dephosphorylates Ser-19 of smooth muscle 
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MLC  halting  progressive  cross-bridge  cycling.   The  MLCP  holoenzyme  exists  as  a 
heterotrimer, requiring all components for maximum activity.  The active site is the 38-
kDa catalytic subunit of type 1 protein phosphatase (PP1c-δ) (Alessi, MacDougal et al. 
1992; Gong, Cohen et al. 1992).  PP1c-δ is attached to the N-terminus of a 110-kDa 
subunit responsible for regulation and specific binding, aptly named myosin phosphatase 
targeting  subunit  1  (MYPT1)  (reviewed  by  Hartshorne  et  al.  1998;  Ito  et  al.  2004). 
Bound to the C-terminus of MYPT1 is a 20-kDa subunit (M20), for which the function 
has  not  yet  to  been  determined.   MLCP  activity  can  be  modulated  by  site-specific 
phosphorylation or association with endogenous inhibitor molecules.
Because these two enzymes act in direct competition with one another, the ratio of 
MLCK / MLCP activity accounts for the level of Ser-19 phosphorylation on MLC.  A 
high value for the MLCK / MLCP activity ratio correlates to high MLC phosphorylation. 
Though Ca2+ is considered the key regulator of smooth muscle cell behavior because it 
activates  MLCK  (Kamm  and  Stull,  1985),  there  are  several  Ca2+-independent 
mechanisms that modulate MLCK and MLCP activity (Somlyo, Wu et al. 1999).  As 
pharmacomechanical  coupling  of  smooth  muscle  contraction  is  further  elucidated, 
specific  regulation  of  MLCK  and  MLCP  will  allow  scientists  and  physicians  to 
accurately control the activity ratio and consequently the contractility of physiological 
hollow organ systems containing smooth muscle.
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1.3 Calcium Regulation
Calcium is one of the most important intracellular signaling molecules, acting as a second 
messenger for a plethora of cellular activities (Campbell AK, 1983), and has long been 
known to participate in vertebrate smooth muscle contraction (Fay, Shlevin et al. 1979; 
Neering  and  Morgan,  1980;  Morgan  and  Morgan,  1982).   Smooth  muscle  precisely 
manipulates  Ca2+ levels  to  keep  [Ca2+]i low at  rest:  approximately  100nM for  rabbit 
femoral artery (Ratz, 2005) relative to 1.5 mM in the external medium.  Because [Ca2+]i is 
such an significant effector of cellular behavior, the intracellular concentration is highly 
regulated by multiple  ion channels  and pumps,  as  well  as  storage compartments  and 
buffers (Figure 2).  The primary determinant of [Ca2+]i is Ca2+ influx from extracellular 
sources.   Calcium  crosses  the  plasma  membrane  through  L-type  Voltage-Operated 
Calcium Channels (VOCCs) or non-selective cation channels, and also enters the cytosol 
from  stores  in  the  sarcoplasmic  reticulum  (SR).   VOCCs  are  opened  by  membrane 
depolarization,  which is  accomplished by activating non-selective  cation  channels,  or 
inhibiting K+ or Cl- channels that are responsible for cellular resting membrane potential. 
Agonists that act through G protein-coupled receptors (GPCR), e.g. α-adrenergic receptor 
activation, can open VOCCs in the absence of membrane depolarization.  Additionally, 
Receptor-Operated  Calcium Channels  (ROCCs)  facilitate  the  Ca2+ influx  upon  direct 
agonist-induced activation of GPCR.  Intracellular Ca2+ stores in smooth muscle SR are 
released by Ca2+-induced Ca2+-release through Ryanodine receptors or by activation of 
Ca2+-channels  with  inositol  triphosphate  (IP3)  (reviewed  by  Karaki  et  al.  1997;  Lee, 
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Poburko et al. 2002, Wray et al. 2005).  Store-Operated Calcium Channels (SOCCs) act 
to refill the SR Ca2+-stores from the external medium after periods of SR Ca2+ depletion. 
After the stimulus for Ca2+-influx has abated, cells must decrease [Ca2+]i to pre-
activation levels to ensure that subsequent stimulation achieves a comparable increase of 
[Ca2+]i.   Homeostasis  is  recovered  as  the  transmembrane  Ca2+ pump  and  Na+/Ca2+ 
exchanger extrude Ca2+ from the cell or site-specific pumps sequester Ca2+ into the SR.
7
 Figure 2. – Cellular calcium regulation. Diagram showing sources of Ca2+ influx (modified from 
Ratz, 2005). To decrease intracellular Ca2+, ions are pumped out of the cell or sequestered into 
the SR.  VOCC, Voltage Operated Calcium Channel; SOCC, Store Operated Calcium Channel; 
ROCC, Receptor Operated Calcium Channel; SR, Sarcoplasmic Reticulum; IP3, inositol 1,4,5-
triphosphate
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1.4 Calcium Sensitization
Early smooth muscle researchers noted significantly increased stress development 
in tissues contracted with a GPCR-activating stimulus versus a depolarizing (high [KCl] 
solution)  stimulus  despite  equivalent  values  for  [Ca2+]i (Morgan  and  Morgan,  1984; 
DeFeo and Morgan 1985; Himpens and Casteels, 1987; Himpens, Kitazawa and Somlyo, 
1990; Ratz, 1999).  Furthermore, addition of cyclic nucleotides can attenuate force with 
no  concurrent  decrease  in  [Ca2+]i.   Ca2+-clamped  (permeabilized)  smooth  muscle 
stimulated with GPCR agonists or guanosine 5’-O-(3-thiophoasphate) (GTPγS) displayed 
increased  force  and  MLC  phosphorylation  (Ruegg  and  Pfitzer,  1985;  Kitazawa  T, 
Kobayashi S, et al. 1989), reinforcing previous data from intact tissues.  The compiled 
results indicated that the cellular response of smooth muscle to Ca2+ is variable.  For a 
given [Ca2+]i, complex molecular mechanisms increase or decrease contractile force and 
MLC  phosphorylation,  termed  Ca2+-senstization  or  Ca2+-desensitization  respectively. 
Since the  initial  description of  this  phenomenon,  Ca2+ sensitization  has  proven to  be 
equally salient as [Ca2+]i in controlling smooth muscle contraction (reviewed by Savineu 
Marthan, 1997; Somlyo and Somlyo 1998, 2003).  Though Ca2+ sensitization is primarily 
incurred  by modulation of  MLCP activity,  it  can also arise  from differential  MLCK 
activity, thin filament regulation or possibly interaction of heat shock proteins with the 
contractile apparatus and structures that propagate tension (Kubota, Nomura et al. 1992; 
reviewed by Kamm and Stull 2001; Kawano et al. 2002).  
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1.5 GPCR role in Calcium Sensitization
Ca2+ sensitization utilizes multiple signaling pathways to inhibit MLCP activity 
(review Hartshorne 1998; Somlyo 2003), thereby increasing the phosphorylated MLC 
value to promote further force development at constant [Ca2+]i.  A well-documented mode 
of Ca2+-sensitiziation proceeds through transmembrane receptor activation of trimeric G-
proteins containing Gαq or Gα12/13 subunits (reviewed by Somlyo 2003).  Activation of 
these  Gα subunits  results  in  downstream  inhibition  of  MLCP  (Figure  3),  which  is 
primarily mediated by the serine/threonine kinases: protein kinase C (PKC) and RhoA 
coiled-coil  kinase  (ROCK).   The  G-proteins  and  much  of  the  intermediate  protein 
cascade are  localized to  the  plasma membrane,  and therefore require  mobile  effector 
molecules to enact sensitization at the intracellular contractile machinery.
Gαq is activated by a  myriad of agonists,  including: acetylcholine [muscarinic 
M1], α-adrenergic agonists, angiotensin II, ATP [P2x and P2y], histamine [H1], platelet-
derived  growth  factor,  serotonin  [5-HT-1c],  thyrotropin-releasing  hormone  and 
vasopressin.  Upon receptor stimulation, Gαq initiates a protein cascade via activation of 
phospholipase  C  (PLC).   This  enzyme  cleaves  phosphatidylinositol-4,5-bisphosphate 
(PIP2) into IP3, which triggers release of SR Ca2+ stores through agonist-specific channels, 
and  diacylglycerol  (DAG),  a  membrane  bound  molecule  that  activates  PKC  in  the 
presence  of  intracellular  Ca2+.   PKC  phosphorylates  the  17-kDa  PKC-activated 
phosphatase inhibitor (CPI-17, Eto et al. 1995, 1997) at the regulatory Thr-38 residue to 
potentiate the molecule’s inhibitory capacity (Kitazawa, Eto et al. 2003).  Therefore Gαq 
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is able to produce Ca2+ influx, SR Ca2+ release and Ca2+ sensitization simultaneously. 
Although CPI-17 is a very potent MLCP inhibitor, its involvement in Ca2+ sensitization 
depends on the level of cellular expression.  CPI-17 is present in high quantities in tonic 
smooth muscle, while phasic smooth muscle exhibits substantially lower concentrations 
to the point that PKC:CPI-17 mediated Ca2+ sensitization is  physiologically irrelevant 
MLC
MLCp
MLCKMLCK
Ca-CaM
MLCP
MYPT1 MYPT1p
MLCP
αq
12/13
γ
β
GDP
αq
GTP
PL
C
β
PIP2
IP3
DAG
PKC
CPI-17 CPI-17p
SRCa2+
Ca2+
Ca2+
Ca2+
Ca2+
Ca2+
Ca2+
Ca2+
Ca2+
Ca2+
Ca2+
α12/13
GTP
GDI
RhoA
GDP
RhoA
GTP
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Figure 3. - Schematic for GPCR-directed Ca2+ sensitization. Sensitization results from MLCP 
inhibition by CPI-17 and/or ROCK. Gq activates CPI-17 and G12/13 activates ROK (ROCK). 
α,β,γ,  are  the  subunits  of  trimeric  G  protein;  GTP,  guanosine  triphosphate;  GDP,  guanosine 
diphosphate; GDI-RhoA-GDP, inactive RhoA GTPase; RhoA-GTP, active RhoA GTPase; ROK, 
RhoA Kinase (ROCK);  PLCβ,  phospholipase C beta;  PIP2,  phosphatidylinositol  di-phosphate; 
IP3, inositol  1,4,5-triphosphate;  DAG, diacylglycerol;  PKC, protein kinase C; CPI-17, 17-kDa 
PKC-activated phosphatase inhibitor 
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(Kitazawa, Eto et al. 2003).  Moreover, CPI-17 is not expressed by avian smooth muscle 
(Kitazawa, Polzin and Eto, 2004).
Agonists  that  bind  receptors  containing  the  Gα12/13 subunit  mobilize  a  PLC-
independent protein cascade resulting in MLCP inhibition.  The pathway triggered by Gα
12/13 (Fukuhara, Chikumi and Gutkind, 2001) – and also seen in Gαq signaling (Booden, 
Siderovshi and Der, 2002) – utilizes Gα-coupled Guanine Exchange Factors (GEF) that 
facilitate exchange of GDP for GTP in membrane-localized small GTPases, particularly 
RhoA,  the  upstream  activator  of  the  ROCK.   ROCK  phosphorylates  two  threonine 
residues on MYPT1 that leads to inhibition of the MLCP holoenzyme.  Phosphorylation 
of  MYPT1  Thr-853  causes  MLCP  to  dissociate  from  the  phospho-myosin  substrate 
(Velasco, Armstrong et al. 2002) and phosphorylation of Thr-696 directly inhibits MLCP 
activity (Feng, Ito et al. 1999).  MYPT1 has been identified as a primary target of ROCK 
(Kimura,  Ito et  al.  1996,  Velasco et  al.  2002),  but  recent  studies  have indicated that 
MYPT1  is  also  phosphorylated  by  ZIP  kinase  (Borman,  MacDonald  et  al  2002; 
MacDonald, Borman et al. 2001) and integrin-linked kinase (ILK; Deng, Van Lierop et 
al. 2001; Kiss, Muranyi et al. 2002; Niiro and Ikebe, 2001).  Though Gαq and Gα12/13 
commonly promote Ca2+ sensitization by a protein cascade that results in ROCK and/or 
PKC activation, there are additional salient physiological pathways for effector kinase 
activation and subsequent Ca2+-sensitization, including arachidonic acid and other lipid 
derivatives (Feng et al. 1999).  
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1.6 Plasma Membrane and Caveolae
Interactions along the plasma membrane of vertebrate smooth muscle control a 
large contingent of cellular behaviors.  The channels, pumps and GPCRs responsible for 
[Ca2+]i are all situated at the plasma membrane, and it is hypothesized that the crucial 
sensitizing enzyme ROCK may require membrane localization for activation (Ratz 2005). 
The  plasma  membrane  of  smooth  muscle  consists  of  at  least  three  domains:  focal 
adhesions,  dystroglycan  complexes  and  caveolae.   Focal  adhesions  and  dystroglycan 
complexes connect  the intracellular  actin  cytoskeleton to  the extracellular  matrix  and 
integrate tension from adjacent cells to generate macroscopic force.  To accommodate 
much of the biochemical cellular signaling, smooth muscle cells employ the 50-100 nm 
cave-like  invaginations  called  caveolae.   These  structures  are  unique  from  other 
membrane  domains  by  nature  of  their  composition  of  cholesterol,  sphingolipids  and 
proteins – notably caveolin-1 (reviewed by Smart, Graf et al.  1999).  Smooth muscle 
sarcolemma is organized such that caveolae and dystroglycan are frequently co-localized 
while there is virtually no overlap between caveolae and focal adhesions, generating an 
alternating spatial organization.  The caveolin family of proteins functions as scaffold 
proteins for the high density of cellular signaling molecules concentrated at caveolae, 
including  transmembrane  GPCRs,  receptor  Tyrosine  kinases,  PKCs,  members  of  the 
MAP kinase pathway and others (Sargiacomo et  al.  1995).   Studies demonstrate that 
treatment with GPCR agonists promotes the translocation of inactive RhoA (bound to 
RhoA-GDI) from the cytosol to the plasma membrane for activation (Fujihara, Walker et 
al. 1997; Gong, Fujihara 1997; Taggert, Lee et al. 1999).  The localized, activated RhoA-
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GTP  turns  on  ROCK  to  inhibit  MLCP,  indicating  caveolae  as  a  possible  site  for 
regulation of Ca2+-sensitization.   This hypothesis is further supported in studies using 
caveolin-1 knockout and cholesterol-depleted smooth muscle, in which the potency of 
GPCR-activated contraction is significantly reduced compared to KCl stimulation (Drag, 
Verkade et al. 2001; Dreja, Voldstedlund et al. 2002).
1.7 Membrane depolarization with KCl and KCl-induced Ca2+ Sensitization
Due to the considerable number of agonists for Gαq- and Gα12/13-directed Ca2+ 
sensitization,  studying the underlying mechanism for  Ca2+-only contraction in  smooth 
muscle  is  very  complicated.   Therefore,  researchers  attempt  to  circumvent  GPCR 
sensitization  using,  as  a  stimulus,  concentrated  KCl  solution,  which  adjusts  the  K+ 
equilibrium potential and clamps the cell in a depolarized state.  Depolarization allows 
Ca2+ influx through VOCCs to increase [Ca2+]i and to direct activation of CaM:MLCK. 
This technique was based on the premise that [Ca2+]i is the primary regulator of smooth 
muscle  contraction  and  was  postulated  to  circumvent  the  complex  sensitization 
mechanisms inherent in GPCR activation (Karaki 2004).  Contraction devoid of GPCR-
directed  sensitization  has  allowed  detailed  description  of  smooth  muscle  Ca2+ 
sensitization by comparative physiology.
Experimental  use  of  KCl  as  an  electromechanical  stimulus  indicated  the 
involvement of additional mechanisms affecting force development.  KCl has proven to 
nominally activate intracellular signaling pathways, modulating MLCK activity – both 
positively  and  negatively  –  through  activation  of  Ca2+/calmodulin-dependent  protein 
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kinase II (CaMKII) and extracellular signal-regulated kinase (ERK).  Moreover, recent 
studies show that smooth muscle contracted with a concentrated KCl stimulus does show 
moderate  levels  of  Ca2+-sensitization.   Our  laboratory  and  others  have  shown  that 
inhibition of ROCK can greatly attenuate the tonic tension produced by KCl contraction 
(Kupittayanant S, Burdyga and Wray, 2001; Anabuki et al. 2000; Sakamoto, Hori et al. 
2003; Sakurada, Takuwa et al, 2003; Urban, Berg and Ratz, 2003).  Since KCl activates 
smooth  muscle  contraction  by  adjusting  cellular  resting  membrane  potential  and 
consequently opening VOCCs for Ca2+ influx, depolarization and/or elevation in [Ca2+]i 
may lead to ROCK activation and Ca2+ sensitization.  Ca2+ Calmodulin-dependent GEFs 
have  been  found to  activate  the  membrane  protein  Ras,  but  no  Ca2+ activated  GEFs 
associated with RhoA activation have yet been identified.  
Studies in intact rabbit femoral artery demonstrate that KCl causes localization of 
ROCK, but not RhoA, to caveolae (Urban and Ratz 2004; Urban et al. 2003).  However, 
considerable amounts of RhoA are constitutively present at caveolae in the active form 
(the inactive form is bound to GDI in the cytosol), and thus any ROCK localized to the 
plasma membrane can be activated to initiate Ca2+ sensitization.  Muscle activation with 
the Ca2+ channel  agonist,  BayK8644,  has  shown that  ROCK recruitment  to  caveolae 
occurs with Ca2+ influx in the absence of membrane depolarization (Urban, Berg and Ratz 
2003), indicating Ca2+ as a possible stimulus for membrane localization.  Direct activation 
of Ca2+-sensitizing mechanisms by [Ca2+]i would suggest that Ca2+-activated contraction 
and Ca2+ sensitization are one congruent system.
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1.8 Permeabilization
Chemical permeabilization is an important experimental technique that enables 
researchers to dictate intracellular concentrations of salient cellular constituents.  Smooth 
muscle  researchers  frequently  employ chemically  permeabilized  cells  to  examine  the 
effects of constant [Ca2+] on contraction (Kitazawa, Kobayashi et al. 1989).  The precise 
control  of  cytosolic  composition  has  also  allowed  investigation  of  individual  Ca2+-
sensitizing agonists and pathways in a variety of smooth muscle tissues (Anabuki, Hori et 
al. 2000; Sward, Dreja et al. 2000; Takeuchi, Kushida et al. 2004; Durlu-Kandilci and 
Brading 2006).
The four predominant permeabilizing agents utilized in smooth muscle research 
are: Triton X-100, saponin, β-escin and α-toxin.  The first three of these permeabilizing 
agents  are  amphipathic  detergents  that  effectively  disrupt  cellular  membranes  by 
depleting hydrophobic phospholipids.  Depending on the nature of the detergent, various 
degrees  of  permeabilization  and  disruption  of  cellular  mechanisms  can  be  incurred. 
Triton X-100 is  a  non-ionic surfactant  that achieves vigorous permeabilization of the 
sarcolemma and the SR membrane.  Additionally, Triton X-100 abrogates all membrane-
associated processes, uncoupling transmembrane receptors that are largely responsible for 
Ca2+ sensitization (Kitazawa, Takizawa et al. 1999).  Saponin is a class of amphipathic 
molecules  known  to  complex  with  cholesterol  molecules  in  the  plasma  membrane. 
Chemical permeabilization with saponin solution generates 9 nm pores in the plasma 
membrane for transit of small molecules and uncouples membrane receptors involved in 
pharmacomechanical  coupling  of  smooth  muscle  contraction  (Bangham,  Horne  et  al. 
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1962; Kitazawa, Kobayashi et al. 1989).  β-escin enacts a less vigorous permeabilization 
of the cellular membrane than saponin, generating pores that can pass molecules up to 
150 kDa (Iizuka et al. 1994).  Contrasting saponin,  β-escin permeabilized tissues retain 
their receptor signaling mechanisms (Kobayashi, Kitazawa et al. 1989) and show mild 
inhibition  of  SR function,  though  the  SR membrane  remains  intact  (Launikonis  and 
Stephenson  1999).   The  least  destructive  permeabilizing  agent,  α-toxin,  forms  pores 
permeable to small molecules up to 3 kDa, while maintaining SR membrane integrity and 
transmembrane receptor-mediated processes (Kitazawa, Kobayashi et al. 1989).
1.9 Objective
Studies indicating that some level of Ca2+ sensitization participates in a KCl –
induced  contraction  undermine  the  previous  model  depicting  Ca2+ contraction  and 
sensitization as autonomous mechanisms.  A thorough model of KCl-induced contraction 
will allow studies of comparative physiology to improve the understanding of GPCR-
activated contraction.  KCl acts as a depolarizing stimulus, facilitating Ca2+ influx by 
opening of VOCCs, indicating membrane depolarization and/or increased [Ca2+]i as an 
initiator of Ca2+ sensitization through the ROCK pathway.  Permeabilizing arteries with 
β-escin  eliminates  resting  membrane  polarization  and  allows  precise  clamping  of 
effective [Ca2+]i.  The objective of this project is to utilize β-escin permeabilized tissue to 
examine whether Ca2+ is responsible for activation of the ROCK sensitization mechanism 
in rabbit femoral arterial smooth muscle.
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MATERIALS AND METHODS
2.1 Tissue Preparation
Tissues were prepared as previously described (Ratz 2003).  Female New Zealand 
White  rabbits  were  anesthetized  and  killed  as  approved  by  the  Medical  College  of 
Virginia  at  Virginia  Commonwealth  University  Institutional  Animal  Care  and  Use 
Committee protocol #0305-32081.  Femoral arteries were immediately removed and kept 
in cold (4oC) normal physiological saline solution (NPSS; in mM: 140 NaCl, 4.7 KCl, 2.0 
morpholino-propanesulfonic acid (MOPS), 0.02 ethylenediaminetetraacetic acid (EDTA) 
– to chelate heavy metals –, 1.2 Na2HPO4·7H2O, 1.2 MgCl2, 1.6 CaCl2, 5.6 α-D-glucose 
and adjusted to pH 7.4 at 37oC with 5N NaOH).  High purity (18.2 MΩ) deionized water 
was used throughout the study.  Fat and adventitia were mechanically removed under a 
binocular dissecting microscope (Olympus SZX12 or Zeiss 10093) and stored in 4oC 
NPSS for no more than four days.  On the day of experimentation, the endothelium was 
removed from all arteries by gently rubbing a roughened rod of similar diameter through 
the arterial lumen.  The arteries were cut into 2-3 mm rings for experimentation.  
2.2 Isometric Force
Contractile force (F) was measured as previously described by Ratz (1993).  Each 
arterial ring was suspended on two stainless steel pins in separate 5 mL wells (Fig 4 and 
5,  Myograph  System  610M  –  Danish  Myo  Technology,  Denmark);  the  pins  were 
connected to a micrometer for tissue length adjustments and an isometric force transducer 
for force measurement.  Voltage signals from the Myograph were digitized and displayed 
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as  F in  grams on a  computer  screen.   Data  were  acquired through an  analog-digital 
converter 
board (National Instruments)  and analyzed using DASYLab 8.0 (DasyTech, Amherst, 
NH).  Tissues were allowed to equilibrate at 37oC for one hour prior to a “wake-up” 
contraction using potassium physiological saline solution (KPSS; NPSS with 110 mM 
KCl isosmotically substituted for NaCl).  For all tissues, “wake-up” was followed by an 
Figure 4. Model Myograph System-610M; diagram from owners manual.  The system facilitates 
precise control of temperature and tissue length while recording isometric force. Bath solutions are 
changed by vacuum suction to allow rapid changing of experimental milieu.
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abbreviated length-tension curve to identify optimum contraction force (Fo) and length 
(Lo) for each tissue (Herlihy and Murphy 1973; Ratz and Murphy 1987).  
2.2.1 Raw Data
All  raw  data  were  recorded  as  grams  of  force  and  the  graphical  models 
approximated typical force tracings, including “wake-up” and Lo contractions in intact 
tissue (Figure 6) as well as “wake-up”, pCa and PE contractions in permeabilized tissues 
(Figure 7).  Statistics were not compiled for raw data.
2.2.2 Standard Warm-up and Tissue “Wake-up”
After tissue wells had warmed to 37oC, the Myograph system was calibrated using 
the DASYLab software to standardize force recording. Tissues rings were hung on the 
Myograph pins, stretched to 0.5 g force and allowed to equilibrate in aerated NPSS for 
one  hour  at  physiological  temperature  (37oC).   During  warm-up,  tissues  experienced 
stress relaxation, after which they were re-stretched to 0.5 g for five minutes.  The NPSS 
Figure 5. Tissue bath of Danish MyoTech 610M system; photo from owners manual.  The artery 
ring is suspended on two stainless steel pins, one leads to the isometric force transducer and the 
other is attached to the micrometer.
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was then substituted for KPSS for five minutes, eliciting a “wake-up” contraction, then 
relaxed for 15 minutes in NPSS. 
2.2.3 Lo determination
The  optimal  length  of  contraction  (Lo)  for  experimental  artery  rings  was 
determined for individual tissues using an abbreviated length-tension curve (Herlihy and 
Murphy 1973; Ratz and Murphy 1987).  The value of Lo was recorded as the ratio of 
passive force (FP) to active force (FA = FT - FP) and, for rabbit femoral artery, was attained 
within  the  range  of  0.13  ± 0.03,  as  determined by  previous  full  length  tension  data 
(unpublished).  
 The abbreviated length-tension curve began by stretching the tissue in 0.5 
g increments up to 2.0 g force.  The micrometer was then dialed down to a calculated 
passive force value and the tissue was contracted in warm KPSS for five minutes. 
Decreasing the tissue length broke any potential intact latch-bridges and adjusted tissues 
visco-elastically to allow accurate measurement of passive tension.  The indicated dial-
down value was estimated by FP = ((FT * 0.13)/1.13), where 1.13 adjusted for the 
inclusion of FT rather than FA in the formula.  The tissue was relaxed by washing three 
times with NPSS over a period of 15 minutes.  The average force of contraction measured 
immediately prior to washout of KPSS was used in the subsequent abbreviated length-
tension curve.  Abbreviated curves were compiled until the empirical Lo falls within the 
appropriate range.
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Figure  6.  –  Tissue  wake-up  and  Lo  determination.  Tissues  are  warmed  to  physiological 
temperature (37oC) in NPSS for 45’ to 1 hour.  Tissues are stretched prior to contraction for 5’ in 
KPSS to reactivate the tissue.  After wake-up contraction tissues are allowed to relax for 10’ then 
subjected to Lo determination. Tissues are stretched at intervals of 0.5g every 5’ until they reach 
2.0g.  Length is rapidly decreased to reach a predetermined passive force at which point tissues are 
again contracted for 5’ in KPSS.  Tissues are washed twice with NPSS and allowed to relax for 
10’.  This process is repeated at least once more until the passive to active force ratio is 0.13±0.03.
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2.3 Tissue Permeabilization
Artery rings at Lo were washed in calcium-free “relaxing solution” (RS; in mM: 
74.1 potassium methanesulfonate,  4.0  magnesium methanesulfonate,  4.0  Na2ATP, 4.0 
EGTA, 5.0 creatine phosphate, 30.0 PIPES, adjusted to pH 7.1 with 1N KOH and ionic 
strength 0.18 with additional 0.5M potassium methanesulfonate).  All tissues were then 
chemically permeabilized with 100 µM β-escin for 45 minutes at 4oC then 15 minutes at 
30oC.  The initial treatment with β-escin at low temperature facilitated slow penetration 
and/or  binding  of  β-escin  to  the  surface  of  the  smooth  muscle  membrane  (Masuo, 
Reardon et al. 1994).  Artery rings were washed thoroughly with RS then incubated for 
20 minutes at 30oC in RS containing 10 µM A23187, a Ca2+ ionophore that depleted SR 
Ca2+. 
To  reactivate  permeabilized  tissues,  each  underwent  an  internal  control 
contraction where [Ca2+] was clamped at pCa 6.0 (1 µM CaCl2) in “contracting solution”, 
which was made by adding 1 M CaCl2 stock (Fluka Chemicals) to RS in appropriate 
amounts as determined by WEBMAXC (Patton,  Thompson et  al.  2004).  The tissues 
were contracted for 10 minutes and then allowed to relax in RS with 10  µM A23187. 
The peak of this internal control contraction was used to normalize data recorded during 
experimental treatment.
2.4 Calcium Concentration Response Curve
Permeabilized tissues underwent an internal control contraction and relaxation at 
30oC followed by 15-minute incubation in the presence of specific kinase inhibitors.  A 
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force-pCa concentration response curve (CRC) was constructed using eleven solutions of 
different [Ca2+], increasing incrementally from 3.16 x10-8 (pCa = 7.5) to 10-5 (pCa = 5). 
Contractile  force  was  allowed  to  plateau  before  the  solution  was  exchanged  for  the 
subsequent Ca2+ concentration.  Artery rings were then relaxed in calcium-free RS.  Raw 
data were collected and normalized before statistics were run.
2.5 PE Sensitization Experiment – Permeabilized Tissue
Tissues were permeabilized and underwent an internal control contraction.  After 
full relaxation, each tissue was incubated in a specific enzyme inhibitor for 15 minutes, 
except for the myristolated PKC peptide inhibitors, which were preloaded for one hour. 
Control tissues received either no inhibitor or the vehicle used to dissolve the inhibitor. 
Tissues  were  immersed  in  pCa 6.25  solution  to  generate  a  sub-maximal  contraction. 
Once steady-state was reached in pCa 6.25 solution, contractions were potentiated with 1 
µM  phenylephrine  (PE)  to  promote  α-adrenergic  receptor-induced  Ca2+-sensitization. 
After 10 minutes of sensitized contraction, myograph baths were repeatedly flushed with 
RS to relax tissue.
In  experiments  to  explore  percent  relaxation  of  PE sensitization,  tissues  were 
allowed to fully relax for 15 minutes subsequent to internal control contraction, without 
preloading of kinase inhibitors.  Sub-maximal contraction was accomplished with pCa 
6.25 and Ca2+ sensitization with 1  µM PE.  Five minutes after  potentiation with PE, 
inhibitors were administered to experimental tissues.  Data were recorded until steady-
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state was reached, approximately 10 minutes after drug introduction.  Tissues were then 
washed with calcium-free RS to initiate relaxation.
Figure 7. – Permeabilization, internal control contraction and PE sensitization. Tissue undergoes 
permeabilization in 100 μM β-escin in relaxing solution (RS) at two temperatures. The tissues are 
then  submerged  in  RS  containing  the  ionophore  A23187  prior  to  contraction  with  pCa  6.0 
contracting solution that generates an internal control. Tissues are relaxed for 15’ in RS + A23187 
containing the experimental inhibitor treatment. A submaximal contraction is elicited with pCa 
6.25 solution and which is then titrated with 1 μM PE for force potentiation. Finally, tissues are 
washed with RS + A23187 to abolish contraction.
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2.6 PE Sensitization Experiment – Intact Tissue
To determine effects of β-escin permeabilization on Ca2+-induced contraction and 
PE-induced  sensitization,  intact  tissues  were  subjected  to  a  similar  protocol  for 
comparison.  Intact artery rings experienced the same regimen of solution changes and 
temperature treatments as permeabilized tissues though the intact tissues were immersed 
in NPSS through the duration.  A sub-maximal contraction comparable to pCa 6.25 in 
skinned tissue was achieved at pCa 3.7 as identified on a previously generated Ca2+-dose 
response curve for intact tissue (unpublished data from Ratz laboratory).  Corresponding 
to the time of pCa 6.25 treatment, intact tissues were titrated with 1 μM of 1M CaCl2 and 
120 μM of 2.5 M KCl, to depolarize the membrane and contract the artery.  After steady-
state had been reached, tissues were stimulated with 1 µM PE for 10 minutes at which 
point they were washed with NPSS to induce relaxation.
2.7 MYPT1 and MLC Phosphorylation
One-dimensional Western Blotting was performed as previously described (Porter 
et al. 2006) to measure the degree of MYPT1-p at Thr-853 and Thr-696 as well as MLC-
p at Ser-19.  Arteries were quick-frozen in 20oC acetone/dry ice slurry at multiple time 
points  –  basal,  pCa  6.25  steady state,  PE  sensitized  –  then  slowly  warmed to  room 
temperature in acetone containing 4% trichloroacetic acid.  Tissues were washed in cold 
acetone  to  remove trichloroacetic  acid,  dried,  weighed and  homogenized  in  a  buffer 
containing 8 M urea, 2% Triton X-100, and 20 mM dithiothreitol.  Homogenized samples 
were heated to 100oC for 10 minutes, clarified by centrifugation and assayed for protein 
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concentrations.  Proteins were separated by molecular weight via Tris/Gly SDS-PAGE 
and transferred (110V, 4oC, 1hr)  onto Immobulin poly(vinylidene diflouride)  (PVDF) 
membranes (Millipore Co.; Bedford, MA).  Membranes were soaked in 3% milk TTBS 
solution, containing 0.1% Tween 20, to block non-specific antibody binding sites and 
then  treated  with  primary  antibody  at  4oC  overnight.   MYPT1  phosphorylation  was 
quantified  using  anti-MYPT1-p853  and  anti-MYPT1-p696  antibodies  (polyclonal 
antibodies produced in rabbit, Millipore Co.; Bedford, MA).  Total MYPT1 (monoclonal 
antibody produced in  mouse,  BD Transduction;  Franklin  Lakes,  NJ)  was assessed to 
ensure loading accuracy.  The relative degree of MLC phosphorylation was determined 
using a rabbit-derived anti-MLC-pSer-19 polyclonal antibody and a mouse-derived anti-
MLC monoclonal antibody (Sigma; St. Louis, MO).  After washing with deionized H2O 
and  TTBS,  secondary  antibody  (goat-anti-mouse  or  goat-anti-rabbit,  as  needed)  with 
horseradish  peroxidase-conjugated  IgG (Sigma;  St.  Louis,  MO) was  added in  target-
specific dilutions [MYPT1-pThr-853 1:4,000; MYPT1-pThr-696 1:5,000; MYPT1 Total 
1:5,000; MLC-p 1:10,000; MLC Total 1:10,000] for 1 hour.  Membranes were washed 
three times with TTBS for five minutes each, after which protein blots were visualized by 
enhanced chemiluminescence (ECL, GE Healthcare; Buckinghamshire, UK).  To account 
for gel-to-gel variability of ECL intensity, a standard control channel was included in 
each gel and band intensities from experimental lanes were reported as fold-control.
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2.8 Drugs and Solutions
H-1152, Y-27632, GF109203X, KN92, KN93, and cell-permeable (myristolated) 
pseudosubstrate peptide inhibitors of PKCζ and PKCα/β were from EMD Biosciences 
(formerly Calbiochem), San Diego, CA.  β-escin and phenylephrine were from Sigma 
Corporation, St. Louis, MO. Wortmannin was from Alexis Biochemicals, San Diego, CA. 
Staurosporine was from Cayman Chemical (Ann Arbor, MI) and A23187 was provided 
by Fisher Scientific, Pittsburg, PA.
GF109203X,  wortmannin,  staurosporine  and  A23187  were  dissolved  in 
dimethylsulfoxide  (DMSO),  while  all  other  compounds  were  dissolved  in  deionized 
water.   Permeabilizing solution was generated by dissolving solid  β-escin in relaxing 
solution.  Vehicles (DMSO and ethanol) were added at final concentrations no more than 
0.1%, which had no effect on KCl-induced contractions.
2.9 Statistics
The  n value for each experiment comprised the number of rabbits from which 
arteries were harvested.  Raw data were recorded, normalized and entered into GraphPad 
Prism  5.0  (GraphPad  Software,  Inc.,  San  Diego,  CA).   The  null  hypotheses  were 
examined using a one-way analysis of variance (ANOVA) and were rejected at p<0.05. 
Differences between experimental groups were analyzed using the Neuman-Keuls post-
hoc  test.   Alternatively,  the  student’s  unpaired  t-test  was  used  to  determine  whether 
normalized data were different than unity (one) and the null hypothesis was rejected at 
p<0.05.  In PE sensitization experiments, normalized steady-state tension was used to 
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observe  deviations  in  pCa  6.25  contractions.   Because  PE  treatment  did  not  create 
identical  force  profiles,  total  area  under  the  force  curve  was  employed  to  analyze 
differences between PE contractions.  The areas of the force versus time curve above the 
pCa  6.25  steady-state  were  compared  by  ANOVA  to  identify  differences  in  PE 
potentiation.   Calcium  dose  response  curves  were  assembled  using  the  Prism  “Log 
agonist-response” equation: Y=Minimum + (Maximum – Minimum)/(1+10^((LogEC50 – 
X)*Hillslope)), where X was the pCa value and Y was the force, to generate sigmoidal 
pCa-force curves.  Statistics were examined for the four defining parameters: Maximum, 
Minimum, LogEC50, and Hillslope.  Graphical representations were based on curve-fit 
data  incorporating  the  average  of  these  four  parameters  across  all  empirical  curves. 
Statistical analyses and curve fitting were performed using Prism 5.0 and SigmaPlot 9.01 
(Systat Software, Inc., San Jose, CA).
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RESULTS
3.1 Calcium Concentration Response Curves (CRCs)
The pCa-force curves for  β-escin skinned tissues complemented the curves for 
other permeabilizing agents previously developed in the Ratz lab (Clelland, 2007).  To 
specifically examine the involvement of particular kinases in Ca2+-only contraction,  it 
was  necessary  to  compile  Ca2+ CRCs  for  a  range  of  protein  inhibitors.   Tissues  in 
calcium-free relaxing solution were preloaded with the kinase inhibitors for a period of 
15 minutes.  Kinase inhibitors were also added to all of the contracting solutions utilized 
to  construct  the  CRCs.   Figure  8A-E  displays  the  curves  generated  for  1  μM 
staurosporine  (non-specific  Ser/Thr  kinase  inhibitor),  1  μM  wortmannin  (MLCK 
inhibitor), 3 μM H-1152 and 10 μM Y-27632 (ROCK inhibitors) and 1 μM GF109203X 
(conventional and novel PKC inhibitor).  Maximum and minimum tension, LogEC50 and 
Hill  Slope  [Table  1  and  Table  2]  values  were  compared  to  control  values  to  assess 
differences between resultant curves.  
The necessity of a kinase cascade for smooth muscle contraction was reconfirmed 
when 1 µM staurosporine completely abolished contraction through all Ca2+ doses (N=3). 
The  staurosporine  curve  had  a  negative  Hill  Slope,  correlating  increasing  Ca2+ 
concentration to a small decrease in force.  The expected inhibition of MLCK with 1 µM 
wortmannin produced a depression in maximum force development [p<0.0001, N=3] and 
shifted the curve to the right, displaying higher LogEC50 [p<0.05].  The minimum force 
and Hill Slope of the wortmannin curve coincided with values from the control CRC.  
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Figure 8. – Calcium concentration response curves (CRCs). (A) 1 µM Staurosporine, (B) 1 µM 
Wortmannin, (C) 3 µM H-1152, (D) 10 µM Y-27632 and (E) 1 µM GF109203X with CRCs for 
corresponding control tissues represented as dashed lines.
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 When permeabilized tissue was treated with 1  µM GF109203X, the maximum 
force was reduced to 20% of the maximum in the control curve showed [p<0.0001, N=4]. 
The minimum force value, LogEC50 and Hill Slope all coincided with the control curve 
when  PKC  activity  had  been  blocked.   Ca2+-dose  response  curves  for  the  ROCK 
inhibitors, H-1152 (3  µM, N=8) and Y-27632 (10  µM, N=5), did not differ from the 
minimum force of the control curve, but they exhibited a decrease in maximum force 
[p<0.0001 for both].  Inhibition of ROCK did not alter the LogEC50 or the Hill Slope of 
the generated curves for H-1152 or Y-27632. 
Staurosporine [N=3] Wortmannin [N=3]
C E C E
MIN 0.00 -0.28±0.02∗ 0.00 0.00
MAX 1.07±0.14 -0.02±0.19∗ 1.38±0.23 0.86±0.13∗
EC50 5.94±0.05 6.20±0.48 6.20±0.02 5.80±0.08∗
Hill 3.70±0.17 -20.3±9.6∗ 4.28±0.17 2.87±0.45
H-1152 [N=8] Y-27632 [N=5] GF109203X [N=4]
C E C E C E
MIN 0.00 0.00 0.00 0.00 0.00 0.00
MAX 1.13±0.12 0.84±0.08∗ 1.14±0.20 0.69±0.08∗ 0.69±0.08 0.19±0.07∗
EC50 5.96±0.09 6.00±0.07 6.14±0.12 6.09±0.12 5.56±0.05 5.45±0.09
Hill 3.70±0.26 4.50±0.28 3.52±0.60 4.05±0.72 3.46±0.47 16.1±12.5
Table  1. –  CRC parameters  for  Staurosporine  [1  μM] and  Wortmannin [1  μM].   Values  for 
minimum (MIN) and maximum (MAX) force,  LogEC50 (EC50)  and  HillSlope  (Hill)  for  the 
CRCs of the control (C) and experimental (E) treatments along with standard error values. [* = 
p>0.05 relative to the corresponding control value]
Table 2. – CRC parameters for  H-1152 [3  μM], Y-27632 [10  μM] and GF109203X [1  μM]. 
Values for minimum (MIN) and maximum (MAX) force, LogEC50 (EC50) and HillSlope (Hill) 
for the CRCs of the control (C) and experimental (E) treatments along with standard error values. 
[* = p>0.05 relative to the corresponding control value]
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3.2 Intact versus Permeabilized Femoral Artery
To determine whether Ca2+ sensitization was physiologically viable in skinned 
tissues, arterial rings were contracted with pCa 6.25 solution and sensitized with the α-
adrenergic  receptor  agonist,  phenylephrine  (PE,  1  μM)  in  the  absence  (control)  and 
presence  of  3  μM  H-1152  [Fig  9A].  For  a  comparison,  intact  tissues  were  treated 
similarly, using 0.2 mM CaCl2 (pCa 3.7) in a depolarizing solution (110 mM KCl added 
to RS) that produced F equivalent to that produced by pCa 6.25 in permeabilized tissue. 
Figure 9 displays typical tracings of normalized force for intact tissue [Fig 9A] 
and  β-escin  permeabilized  tissue  [Fig  9B]  treated  with  pCa  3.7  and  pCa  6.25, 
respectively,  followed  by  1µM  PE.   Force  values  were  normalized  to  the  control 
contraction produced.  Upon treatment with 1 µM PE, intact and permeabilized control 
tissues showed marked increase in tension above that induced by stimulation with a sub-
maximal Ca2+ concentration.  When pretreated with 3  μM H-1152, the maximum PE-
induced force was abrogated in both intact (90%±1% inhibition) and skinned (63%±8) 
rabbit femoral artery [Fig 1C], confirming that ROCK played a substantial role in Ca2+ 
sensitization  after  permeabilization.   Importantly,  3  μM  H-1152  also  significantly 
inhibited steady-state tension developed upon stimulation of intact muscles with pCa 3.7 
(50%±8%) and skinned muscles with pCa 6.25 (30%±7%) [Fig 1D].  The decrease in 
Ca2+-generated force by the ROCK inhibitor indicated that Ca2+ sensitization could occur 
as the result of direct activation of ROCK by [Ca2+]i.  This experiment confirmed that 
cellular  signaling mechanisms responsible for Ca2+ sensitization could survive  β-escin 
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cellular permeabilization, allowing examination of Ca2+-induced Ca2+ sensitization in a 
Ca2+-clamped preparation. 
Figure 9. – Intact vs. permeabilized artery treated with 3 µM H-1152. (A) Force tracing for intact 
tissue, (B) force tracing for tissue permeabilized with 100 µM β-escin, (C) contractile force when 
contracted with Ca2+ solution relative to control, and (D) contractile force when potentiated with 
1 µM PE relative to control [N=3, *=p<0.05]
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3.3 ROCK Inhibition of PE Sensitization
To elucidate  the involvement of ROCK in Ca2+-  and PE-induced contractions, 
further experiments using the above protocol  examined the correlation between force 
development  and  MYPT1  and  MLC  phosphorylation  levels.   Figure  10  displays  a 
representative force tracing for two skinned femoral arteries, one acted as a control while 
the other was pretreated with 3 µM H-1152 [Fig 10A].  The specific ROCK inhibitor Y-
27632 was used to  confirm the data  obtained with H-1152.   Ca2+-induced force was 
significantly below the control in tissue rings pretreated with 3 µM H-1152 (24%±6%) 
and 10 µM Y-27632 (32%±14%) [Fig 10B].  Pretreatment with 3 µM H-1152 and 10 µM 
Y-27632  also  prevented  a  significant  increase  in  force  due  to  α-adrenergic  Ca2+ 
sensitization  initiated  with  1  µM PE (44%±15% [N=5,  p>0.05]  and  80%±3% [N=4, 
p>0.0001] respectively).  
One-dimensional Western blot analysis was undertaken to compare the relative 
phosphorylation levels of MYPT1 and MLC in a tissue pretreated with 3  µM H-1152 
versus control.  Tissues were frozen at the plateau of a pCa 6.25 contraction as well as 
two minutes after administration of 1 µM PE.   Addition of 1 µM PE produced qualitative 
increases  in  MYPT1  phosphorylation  at  Thr-853  (34%±37%)  and  Thr-696 
(560%±332%), as well as MLC phosphorylation at Ser-19 – all indicators of sensitized 
contractile force.  3  µM H-1152 eliminated MYPT1 phosphorylation at Thr-853 during 
both  Ca2+ contraction  and  PE-sensitization  [Fig  10C],  but  there  was  no  change  in 
MYPT1-pThr-696  or  total  MYPT1  [data  not  shown].   Western  Blots  for  MLC 
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phosphorylation indicated that 3 µM H-1152 prevented an increase in MLC-p Ser-19 [Fig 
10D].
Figure 10. – Inhibition of PE-induced sensitization by pretreatment with ROCK inhibitors. (A) 
Typical force tracing for inhibition of pCa 6.25 and PE-direct contraction by 3 µM H-1152, (B) 
pCa 6.25 with H-1152 [N=6] and Y-27632 [N=4], (C) MYPT1-p Thr-853 [N=3], and (D) MLC-p 
Ser-19 [N=3] [*=p<0.05]
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3.4 Additional Kinases in PE Sensitization
After  observing  that  H-1152  was  comparably  effective  in  skinned  and  intact 
tissues  for  inhibition  of  both  calcium-induced  and  PE-induced  contraction,  the  same 
protocol was used to examine the effect of inhibiting other kinases included in traditional 
Ca2+ sensitization  models.   The  targets  of  inhibition  were  protein  kinase  C  (PKC), 
Calmodulin-dependent  kinase  (CaMKII)  and  MLCK;  additionally  a  general  Ser/Thr 
kinase inhibitor, 1 μm staurosporine, was also used to inhibit ILK but not ZIP kinase. 
The general PKC inhibitor, GF109203X, and peptide pseudo-substrate inhibitors 
for PKCα/β and PKCζ/λ isoforms were utilized to explore the behavior of PKC in Ca2+-
induced Ca2+-sensitization.  During pCa 6.25 contraction, arterial rings pretreated with 1 
µM GF109203X and 10 µM PKCα/β peptide inhibitor displayed significant reduction of 
force (25%±10% and 36%±11% inhibition respectively) [Fig 11A], though there was no 
force  reduction  due  to  incubation  of  tissues  in  10  µM  PKCζ/λ  peptide  inhibitor. 
Interestingly, none of the PKC inhibitors at the aforementioned concentrations obstructed 
PE-directed  Ca2+ sensitization  [data  not  shown].   CaMKII  was  documented  to  be 
activated  by  Ca2+ upstream  of  ROCK,  and  could  participate  in  ROCK  activation 
(Sakurada et  al.  2003).   However,  KN-93,  a  CaMKII inhibitor,  did not  inhibit  Ca2+-
induced contraction [Fig 11B].  Inhibition of MLCK with 1  µM wortmannin reduced 
force development in pCa 6.25 solution by 76%±1% [Fig 11C] and also suppressed the 
PE Ca2+ sensitization effect  by 69%±7% [Fig 11D].   Staurosporine  at  1  µM inhibits 
MLCK, ROCK, PKC, ILK and others, but the drug must be present at 10 µM to inhibit 
ZIP kinase (Niiro and Ikebe 2001).  Since 1  µM staurosporine fully eliminated force 
37
development  the data  suggest that  ZIP kinase played no role in Ca2+-induced or  PE-
induced force development.
A.
Te
ns
io
n 
(F
ol
d-
C
on
tro
l)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Co
nt
ro
l
G
F1
09
20
3X
PK
C
ζ / λ
PK
C
α /
β
B.
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
C.
Te
ns
io
n 
(F
ol
d-
C
on
tro
l)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
D.
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Co
nt
ro
l
KN
-9
2
KN
-9
3
Co
nt
ro
l
St
au
ro
sp
or
in
e
W
or
tm
an
ni
n
Co
nt
ro
l
St
au
ro
sp
or
in
e
W
or
tm
an
ni
n
∗
∗ ∗
∗
∗
∗
Figure 11. – Inhibition of Ca2+- and PE-induced sensitization with kinase inhibitors involved in 
the  Ca2+ sensitization  pathway.  (A)  pCa  6.25-induced  force  during  PKC  inhibition  with 
GF109203X [N=4]  and pseudo substrate  inhibitors  [N=3],  (B)  pCa 6.25-induced  force  in  the 
presence of CaMKII inhibitors [N=3], (C) pCa 6.25-induced force and (D) PE-induced force for 
Wortmannin [1 µM, N=3] and Staurosporine [1 µM, N=3]. [*=p<0.05]
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3.5 Percent Relaxation
Exposing tissues to protein kinase inhibitors subsequent to onset of α-adrenergic 
Ca2+ sensitization facilitated identification of kinases that were actively involved in PE-
induced force maintenance.  Drugs were introduced after stimulation with 1 µM PE for 
five minutes, the approximate time to reach maximum force and MLC phosphorylation 
(Somlyo 1997).  The control tissue exhibited a small amount of relaxation (12%±3%) 
over the five minute contraction, as documented in the force tracing in Fig 12A.  The 
effect of experimental drug treatments reported as a % relaxation can be seen in Fig 12B. 
Kinase inhibitors that abrogated PE-induced Ca2+ sensitization through pretreatment also 
caused relaxation far beyond the control tissue: 3  µM H-1152 [Force tracing Fig 12A] 
(45.1%±1.3%, p<0.0001,  N=3),  10  µM Y-27632 (28.9%±3.4%, p<0.05,  N=6),  1  µM 
wortmannin  (47.8%±11.0%,  p<0.0001  N=3),  and  1  µM  staurosporine  (65.0%±9.5%, 
N=3).  Neither 1 µM GF109203X (10.4%±15%, N=3) nor 5 µL DMSO vehicle (12.1%±
3.8%, N=3) deviated from the relaxation observed in the control, which corroborated the 
absence of inhibition when administered prior to PE-directed Ca2+-sensitization. 
3.6 Basal MYPT1-p and MLC-p
KCl-induced Ca2+ sensitization may be the result of Ca2+ directly activating the 
ROCK sensitization pathway, or alternately, constitutive ROCK activation could provide 
basal Ca2+ sensitization.  To examine basal activity, skinned tissues were incubated in RS 
with kinase inhibitors, frozen and then analyzed via 1-D Western Blot.  Decreases in 
MYPT1  and  MLC  phosphorylation  would  indicate  that  the  inhibited  kinase  was 
constitutively active and contributed to basal Ca2+-sensitization.  Inhibition of ROCK
39
Figure 12. – Percent  relaxation from maximum PE-induced force.  (A) Typical  force 
tracing for administration of 3 µM H-1152 after 5 minutes of PE-induced contraction and 
(B) percent relaxation for specific kinase inhibitors [N=6 for Y-27632, N=3 for all others 
* = p>0.05]
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using 3 µM H-1152 decreased MYPT1-pThr-853 [Fig 13A, p<0.0001, N=9] and MLC-p 
Ser-19 [Fig 13B, p<0.0001, N=9], though there was no significant change in MYPT1-
pThr-696 (data not shown).  These results were reinforced by experiments with 10 µM Y-
27632, which also decreased MYPT1-pThr-853 [p<0.001, N=4] and MLC-p [p<0.0001, 
N=4] and similarly showed no significant alteration of MYPT1 Thr-696 phosphorylation. 
Interestingly,  H-1152  administered  at  1  µM  significantly  reduced  MYPT1-pThr-853 
[p<0.001, N=3], but although the average MLC-p value was less than the control value 
this reduction was not statistically significant [p=0.24, N=3].  Inhibition of PKC using 1 
µM GF109203X produced a non-significant increase of the average MYPT1-pThr-853 
value, and was coupled with a decrease in MLC-p [p<0.05, N=3].  
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Figure 13. – Basal phosphorylation of MYPT1 Thr853 and MLC in calcium-free solution. (A) 
MYPT1-p Thr-853 relative to control [N=3], (B) MLC-p Ser-19 relative to control [1µM H-1152 
and GF109203X, N=3; Y-27632, N=6; 3µM H-1152, N=9; * = p>0.05]
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DISCUSSION
Results from the present study support the hypothesis that ROCK participates in 
KCl-induced Ca2+ sensitization.   Chemically permeabilized (“skinned”) rabbit  femoral 
arteries treated with ROCK inhibitors H-1152 or Y-27632 showed decreased pCa 6.25-
induced and α-adrenergic GPCR-induced contraction compared to tissues not treated with 
ROCK  inhibitors  (control).  Moreover,  the  maximum  force  produced  during  a  Ca2+ 
concentration response curve (CRC) was also reduced by ROCK inhibition.   H-1152 
significantly decreased phosphorylation of the MLCP regulatory site MYPT1-pThr-853 
during  sub-maximal  Ca2+-induced  contraction  and  PE-induced  force  potentiation. 
Importantly,  skinned tissues  treated with ROCK inhibitors  in  a  calcium-free  solution 
showed  decreased  MYPT1-pThr-853  and  MLC-p,  suggesting  that  ROCK  was 
constitutively  active,  and  was  responsible,  at  least  in  part,  for  basal  MLC-p  in 
unstimulated muscle.  Incorporation of constitutive ROCK activity into the current model 
of smooth muscle contraction would account for the observation of Ca2+ sensitization by 
KCl contraction without  necessitating activation of  ROCK via depolarization or  Ca2+ 
influx.  The description of Ca2+ sensitization as a leftward shift in the pCa-force curve 
remains  a  valid  assertion,  but  our  data  suggests  that  the  current  model  of  Ca2+ 
sensitization may need to be adjusted to account for the effect of basal regulation of 
MYPT1 and MLC phosphorylation by kinases such as ROCK.  
The presence of constitutive ROCK activity does not negate the possibility of 
additional sensitization due to depolarization or indirect Ca2+ activation of sensitizing 
pathways.  Chemical permeabilization of femoral arteries facilitated the investigation of 
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the KCl-directed sensitizing stimulus by abrogating resting cell membrane polarization, 
effectively eliminating one of two possible stimuli  (depolarization and/or increases in 
[Ca2+]i),  and  allowed us  to  directly  test  the  hypothesis  that  Ca2+ can  activate  ROCK 
leading  to  Ca2+ sensitization.   Permeabilization was performed with the technique of 
Kitazawa  (1989),  but  multiple  protocols  were  tested  to  identify  the  appropriate 
temperature and time period for permeabilization for New Zealand White rabbit femoral 
artery.   Permeabilization  trials  included experimentation  with  1  μM wortmannin  that 
demonstrated that MLCK inhibition markedly attenuated force, indicating minimal loss 
of calmodulin over the experimental duration thus obviating the need to reintroduce the 
enzyme into the experimental milieu.
The  attenuation  of  force  by  ROCK  inhibitors  could  result  from  one  of  two 
possible mechanisms: reduction of the basal level of MLC-p prior to activation of MLCK 
or by inhibition of the amount of MLC-p increase during muscle activation (Figure 14). 
Our data demonstrate a significant decrease of basal MLC-p by ROCK inhibitors and 
therefore support the inhibitory model seen in Figure 14C  A recent study by Rembold et 
al. indicates that 15% of cellular MLC must be phosphorylated before appreciable levels 
of active force can be generated (Rembold et al. 2004). No basal inhibition of force was 
observed  in  tissues  treated  with  ROCK  inhibitors  despite  significant  reduction  in 
MYPT1-pThr853 and MLC-p.  Therefore the inhibition of basal MLC phosphorylation 
may represent a newly described regulatory mechanism that would be expected to control 
the degree of force induced by any contractile stimulus.
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Staurosporine (1 μM) administration produced a CRC with a negative Hill Slope, 
representing a small decrease in force with increasing Ca2+ concentration.  The decrease 
in  force  with  increasing  [Ca2+]  was  likely  due  to  visco-elastic  relaxation  over  the 
extended  time  course  or  activation  of  calcium-dependent  proteases  at  high  [Ca2+]i. 
Alternatively,  the data  suggest  that  another  kinase,  possibly ILK, may adjust  passive 
force.  Passive force is adjustable in bladder smooth muscle (Speich, et al. 2007), but 
whether that is also true for vascular smooth muscle (VSM) remains to be determined. 
Figure 14. – Mechanism of MLCp inhibition.  Reduction of MLCp could occur through one of 
two  possible  mechanisms  to  achieve  the  same  final  degree  of  phosphorylation  and  force 
development. (A) The cycle of phosphorylation of MLC [k1 = MLCK rate constant; k2 = MLCP 
rate  constant],  (B)  the  basal  phosphorylation  is  constant  and  the  extent  of  increase  upon 
stimulation is lessened or (C) the baseline phosphorylation is decreased and the degree of increase 
due  to  stimulation  is  unchanged.   The  true  mechanism is  likely  a  combination  of  these  two 
disparate ideas.
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The absence of  any force development  in  the presence  of  staurosporine supports  the 
model of smooth muscle contraction that requires Ser/Thr phosphorylation.  The CRC 
produced  in  the  presence  of  wortmannin  displayed  significant  inhibition  of  force, 
reinforcing a predominant role for MLCK in permeabilized VSM.  However, there was 
considerable force development (60% fold-control) produced at the highest pCa value 
used during the CRC in the presence of 1 μM wortmannin though this concentration of 
inhibitor is reported to achieve 90% inhibition of MLCK (Davies, Reddy et al. 2000). 
The presence of considerable contraction despite the potent inhibition of MLCK infers 
the  possibility  of  MLCK-independent  phosphorylation  of  MLC  leading  to  force 
development,  for  which  function  ROCK  has  been  identified  (Amano  et  al.  2002). 
Because staurosporine abolished the ability of Ca2+ to cause contraction but ROCK, PKC 
and MLCK inhibition did not, these data suggest that another kinase may also play a role 
in regulation of Ca2+-dependent MLC-p. Of the two most likely candidate kinases, our 
data support the hypothesis that ILK rather than ZIP kinase played in a role in rabbit 
femoral artery because 1μM staurosporine inhibits ILK but not ZIP kinase (Niiro and 
Ikebe 2001).
The  ROCK  inhibitors,  H-1152  and  Y-27632,  produced  similar  CRCs  with 
decreased maximum force relative to control tissues, indicating participation of ROCK in 
Ca2+-induced contraction.  PKC also played a substantial role in Ca2+-induced contraction, 
as seen by the ~70% inhibition compared to control when tissues were treated with 1 μM 
GF109203X.  These results correlate to traditional models of Ca2+ sensitization mediated 
by PKC and ROCK separately, but also support recent findings that PKC activates the 
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RhoA/ROCK pathway (Sivasankaran et al. 2004, Baek, Jeon et al. 2008).  The presence 
of PKC as an upstream activator of ROCK would account for the considerably larger 
inhibition by GF109203X compared with the ROCK inhibitors.  Therefore, PKC may 
have caused sensitization via CPI-17 inhibition of MLCP as well as activation of ROCK 
to phosphorylate MYPT1-pThr853, potentiating the inhibition.  Western blots for tissues 
at rest in calcium-free solution demonstrate that GF109203X treatment reduced MYPT1-
pThr-853 phosphorylation as well as MLC-p to a degree comparable to ROCK inhibitors, 
although MYPT1 is not a preferred PKC substrate.
Comparison  between  intact  and  β-escin  permeabilized  femoral  arteries  was 
completed to ensure physiological relevance of the permeabilization technique.  Results 
showed equivalent levels of contraction using pCa 3.7 in the presence of depolarizing 
solution for intact tissues and a pCa 6.25 solution in skinned tissues, as well as equivalent 
further contraction induced by addition of 1  µM PE at steady state of the contraction 
induced by Ca2+.  In intact and skinned tissues, inhibition of ROCK with 3 µM H-1152 
significantly decreased tension during Ca2+- and PE-induced contractions.  Due to the 
similar  results  in  intact  and  skinned  muscles,  the  β-escin  treatment  regimen  can  be 
concluded  to  generate  viable  permeabilized  cells  while  maintaining  the  biochemical 
signaling  pathways  involved  not  only  in  PE-induced,  but  also  Ca2+-induced,  ROCK-
dependent  Ca2+ sensitization.   In  short,  these  data  support  the  hypothesis  that  KCl-
induced Ca2+ sensitization  can  be  attributed  to  Ca2+-induced Ca2+ sensitization  and/or 
constitutive ROCK activity.  Western blot analysis of MYPT1 and MLC phosphorylation 
showed that during pCa 6.25 contraction, MYPT1-pThr-853 was reduced 10-fold by 3 
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μM H-1152 relative to the control tissue, but drug treatment had no effect on MYPT1-
pThr-696 or MLC-p Ser-19.  The absence of a detectable decrease in MLC-p concomitant 
to decreased MYPT1-pThr-853 could be because sub-maximal Ca2+ stimulation promotes 
a  minimal  change  in  MLC-p beyond  the  resolution  of  our  measurements.   The  PE-
directed phosphorylation of MYPT1 and MLC was abolished by 3 μM H-1152 treatment 
and tissues displayed phosphorylation levels comparable to the control value measured 
prior to PE administration.  This suggests that ROCK acts as the primary kinase in the α-
adrenergic receptor-induced Ca2+ sensitization pathways of permeabilized VSM.
The incubation of salient kinase inhibitors during pCa 6.25 contraction followed 
by  PE  administration  identified  enzymes  involved  in  GPCR  and/or  Ca2+-specific 
contraction.  PE-directed induction of sensitization was significantly inhibited by both 
ROCK inhibitors (H-1152 and Y-27632) as well as by wortmannin and staurosporine, but 
none of the PKC inhibitors caused a decrease in α-adrenergic receptor-stimulated force. 
Relaxation  induced  at  the  peak  of  PE-potentiated  force  further  signifies  integral 
involvement of an enzyme in sensitized force potentiation.  Corroborating the results seen 
when tissues were preloaded with a kinase inhibitors, tissues significantly relaxed when 
inhibitors of ROCK and MLCK were added at the peak of the PE-induced contraction in 
tissues pre-contracted with Ca2+ at pCa 6.25.  This was also true when the general Ser/Thr 
inhibitor staurosporine was used.  The conventional/novel PKC inhibitor, GF109203X, 
did not cause relaxation (i.e., the response in the presence of GF109203X was identical to 
the time-dependent  control  response).   These results  confirm that  ROCK and MLCK 
appear to be integral components of the α-adrenergic receptor-induced Ca2+ sensitization 
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pathway.  However, the data suggest that no PKC isotypes (conventional/novel/atypical) 
are activated by PE, at least under these conditions in which tissues were first contracted 
with Ca2+ at pCa 6.25, then stimulated with a submaximum PE concentration. This is 
contrary to previous studies indicating atypical PKC (PKCζ) activation by high doses 
(100  μM)  of  PE  (Somlyo  1997).   Predominance  of  ROCK  and  absence  of  PKC 
involvement  in  PE-directed  sensitization  indicates  that  α-adrenergic  receptor-induced 
Ca2+ sensitization is accomplished primarily through MYPT1 phosphorylation rather than 
CPI-17 activation.    Furthermore,  this evidence suggests that the potential  interaction 
between the RhoA/ROCK and PKC pathways is unidirectional for PKC activation of 
ROCK since there was no force inhibition by GF109203X when ROCK was certainly 
activated.  The hypothesized activation of ROCK by PKC yields a new model of Ca2+ 
sensitization of VSM (Figure 15).
A comparison between the pCa 6.25 and PE-treated portions of the force tracing 
elucidated involvement  of distinct kinases in two distinct  phases of force production. 
Several  kinases participated in  the  GPCR-activated force development  as  well  as  the 
Ca2+-only component of contraction.  Ca2+ clamped contraction (at pCa 6.25) was reduced 
by  H-1152,  Y-27632,  wortmannin,  staurosporine,  GF109203X  and  the  PKCα/β 
pseudosubstrate  inhibitor.   These  results  support  the  hypothesis  that  ROCK  and 
conventional and/or novel PKC along with MLCK and other Ser/Thr kinases participate 
in  Ca2+-induced  contraction.   At  1μM,  GF109203X  inhibits  conventional  and  novel 
PKCs, but not atypical PKCζ/λ isotypes (Martiny-Baron, Kazanitez et al. 1993).  When a 
specific PKCζ/λ pseudosubstrate inhibitor was administered during the PE sensitization 
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protocol  there  was  no  significant  deviation  from control  at  pCa  6.25  or  during  PE-
induced  force  potentiation.   These  data  coincide  with  the  hypothesis  that  PKCζ/λ  is 
responsible for regulation of Ca2+ levels that can modulate force maintenance (Ratz and 
Miner 2008).  Permeabilization would have disrupted any forms of Ca2+ regulation and 
thus obviated any effect by PKCζ/λ inhibition.
Constitutive ROCK activity and the consequent basal Ca2+ sensitization would 
prime the muscle for rapid contraction upon activation, but also allow for sensitizing or 
desensitizing  modulation  to  account  for  variable  physiological  demands.   Though  a 
transient increase in [Ca2+]i does not upregulate recruitment and activation of cytosolic 
RhoA-GDI to the plasma membrane, a substantial amount of cellular RhoA (18%) is 
basally  localized to  caveolae  in  rabbit  femoral  artery (Urban et  al.  2003).   With the 
considerable quantity of active (GTP-bound) RhoA at the membrane, it is possible that 
sufficient  ROCK  will  be  stimulated  to  generate  modest,  but  significant  basal  Ca2+ 
sensitization.  Caveolin-1 knockout and cholesterol depleted tissues that would eliminate 
caveolae-based  Ca2+ sensitization  show  no  reduction  of  force  in  KCl  contraction. 
However, such experimental set-ups contain inherent disruption of the cellular signaling 
apparatus, which includes regulation of membrane potential and Ca2+ signaling (Darby, 
Kwan and Daniel 2000; Babiychuk, Smith et al. 2004), and cannot conclusively preclude 
caveolae as a possible regulatory site for sensitization.  Contrary to published work, our 
laboratory  has  produced  data  indicating  that  caveolar  disruption  does  inhibit  a  KCl-
induced contraction by ~40%.  Additionally ROCK is involved in maintenance of the 
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GTP
cytoskeleton (reviewed by Riento and Ridley, 2003) and therefore a moderate level of 
activation would account for cellular integrity.
4.1 Translational Relevance
The level of intracellular Ca2+ is an important controller of the two force directing 
mechanisms  in  smooth  muscle  –  Ca2+-induced  contraction  and  Ca2+ sensitization. 
Calcium is particularly salient in the pathophysiology of vascular resistance vessels since 
hypertensive rats are shown to express larger quantities of L-type Ca2+ channels and their 
pore  forming  α1C subunit  that  correlates  to  increased  Ca2+ influx  upon  contraction 
stimulation  and  membrane  depolarization.   Chronic  hypertension  affects  45  million 
individuals in the United States, leading to multiple pathologies.  Abnormal expression of 
L-type VOCCs leading to increased Ca2+ influx and arterial tone is a common observation 
in all forms of hypertension (Sonkusare et al. 2006) and because the expression of these 
VOCCs  is  regulated  at  the  more  complex  gene  stage,  regulation  of  smooth  muscle 
contractility  on  the  side  of  Ca2+ sensitivity  my  provide  an  alternative  location  for 
treatment  to  relax  total  peripheral  resistance.   The  presence  of  constitutive  levels  of 
and/or Ca2+-activated ROCK activity would be expected to facilitate basal sensitization, 
elevating blood pressure.  Controlling the cellular response to Ca2+ is salient in clinical 
application  because  studies  have  shown  that  animals  and  patients  suffering  from 
hypertension display elevated [Ca2+]i compared with normotensive individuals.  Smooth 
muscle contractility is strongly correlated to ROCK function and a detailed understanding 
of the protein cascade would allow improved treatments for disorders of smooth muscle 
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organ  systems.   ROCK  activity  has  proven  particularly  significant  in  treatments  of 
hypertension  and vasospasm in  vasculature.   Uehata  et  al.  demonstrated  that  ROCK 
inhibition  by  Y-27632  substantially  relaxes  arterial  contraction  and  decreases  blood 
pressure  in  hypertensive  rats  (Uehata  et  al.  1997),  suggesting  ROCK inhibition  as  a 
possible therapeutic treatment for hypertension. 
ROCK has been shown to be involved in the enhanced vasoconstriction inherent 
in hypertension (Mukai, Shimokawa et al. 2001) and coronary artery spasm (Kandabashi, 
Shimokawa et  al.  2000;  Shimokawa 2000).   Abrogation  of  coronary  vasospasm was 
accomplished by inhibition of MYPT1 phosphorylation (Kandabashi, Shimokawa et al. 
2000), the main target of ROCK.  A recent study demonstrated that the ROCK inhibitor 
fusadil precluded coronary constriction upon acetylcholine challenge (Masumoto et al. 
2002),  indicating ROCK as a primary mediator of coronary spasm.  This identifies a 
possible therapeutic target for coronary artery spasm, which is the underlying pathology 
in unstable angina, acute myocardial infarction, sudden cardiac death and other ischemic 
heart diseases (Mohri M, Shimokawa H, and Taekshita A 2002).
Furthermore, a recent study of common ROCK polymorphisms in human twins 
indicated  that  the  common  non-synonymous  single  nucleotide  polymorphism  (SNP; 
Thr431Asn) generated phenotypes of higher resting diastolic blood pressure and systemic 
vascular resistance, and altered endogenous renin-angiotensin coupling (Seasholtz et al. 
2006).  Residue 431 is located in the coiled-coil domain of ROCK, which is thought to 
participate in ROCK autoinhibitory dimerization as well as Rho binding and consequent 
activation  (Loriand,  Guérin  and  Pacaud  2006).   The  realization  of  genetic  factors 
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directing ROCK activity provides a possible method for early diagnosis of hypertension 
based on genetic risk factors.
ROCK  involvement  has  been  identified  in  many  vascular  and  cardiac 
mechanisms,  including:  PGDF-induced  VSM  cell  proliferation,  cardiac  myocyte 
differentiation,  vascular  re-stenosis,  atherosclerosis  and  pulmonary  hypertension 
(reviewed by Loriand, 2006). Moreover, ROCK regulates stress fiber formation in non-
muscle cells, contributing to endothelial cell permeability and cellular migration.  These 
phenomena are significant in angiogenesis, tumor metastasis, wound repair and neurite 
retraction in neurons (reviewed by Riento and Ridley, 2003).  With a complete model of 
ROCK function, modulation of the kinase activity could provide therapeutic benefits for 
many disease states.
In  conclusion,  our  data  support  the  hypothesis  that  there  exists  a  degree  of 
constitutive ROCK activity that contributes to basal MLC-p and possibly to Ca2+-induced 
sensitization, resulting in Ca2+ sensitization independent of activation of femoral artery 
GPCRs.   Furthermore,  our  data  support  the  hypothesis  that  certain  PKC  isotypes, 
including PKCα/β may be involved in activation of components upstream from ROCK. 
Further elucidation of the pathways for activation of ROCK and the substrates that this 
enzyme acts upon will prove very significant in the treatment of a myriad of pathologies.
4.2 Further Experiments
- MYPT1-p and MLC-p Western blots examining the difference between basal and 
Ca2+-contracted phosphorylation levels in the presence of ROCK and PKC 
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inhibitors.  The current series of gels showed increases above Ca2+-activated 
levels as a result PE stimulation, but comparison between basal and activated 
states would further elucidate the mechanism for force inhibition.
- Use confocal microscopy to examine the extent of membrane disruption by β-
escin permeabilization.  Extensive damage to caveolae and other membrane 
bound-apparatus could activate/deactivate salient protein cascades.
- Treatment of permeabilized tissues with the BEL compound prior to Ca2+-
clamping.  BEL inhibits phospholipase A2 from producing arachidonic acid, 
which is a known activator of ROCK.  This experiment determines if decrease of 
force with ROCK inhibitors occurs because arachidonic acid is present in the 
experimental milieu.
- Calcium concentration response curves including wortmannin and a ROCK 
inhibitor compared to a control and a tissue treated with 1 µM staurosporine. 
Contraction in the presence of the MLCK and ROCK inhibitors would indicate 
the participation of another kinase in force development.
- Measure CPI-17 phosphorylation in intact and permeabilized tissue during rest 
and stimulation with Ca2+ and/or PE.  This will indicate if the main inhibitory 
mechanism of PKC is to activate CPI-17 for direct inhibition of MLCP or to 
activate the RhoA/ROCK pathway.  The experiment will also help elucidate 
specific roles for different PKC isotypes.
- Perform similar array of experiments in mice with ROCK or PKC knockouts.
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